Bavarian Nordic gets four-year contract for mpox and smallpox vaccine from UK government
Bavarian Nordic gets four-year contract for mpox and smallpox vaccine from UK government COPENHAGEN, Nov 2 (Reuters) - Bavarian Nordic BAVA.CO has received a four-year contract from the British government for its vaccine against mpox and smallpox, the Danish vaccine maker said in a statement on Monday.
Bavarian Nordic will supply its MVA-BN vaccine through scheduled deliveries
The contract also includes optional flexibility provisions
"It is vital to ensure that the UK has the right vaccines available to protect the public from a range of infectious disease threats," the UK Health Security Agency said in the same statement
Bavarian Nordic did not disclose the contract value
Mpox is a viral disease that causes fever and skin lesions and spreads through close physical contact
(Reporting by Louise Rasmussen, editing by Stine Jacobsen)
((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))
Recent news on Bavarian Nordic A/S
See all newsBrief: Bavarian Nordic Completes First Tranche Of Share Buy-Back Program
Bavarian Nordic gets four-year contract for mpox and smallpox vaccine from UK government
Brief: Bavarian Nordic Awarded Multi-Year Vaccine Contract By UK Government
Bavarian Nordic donates 75,000 mpox vaccine doses to global emergency stockpile
Brief: Bavarian Nordic Donates To Global Mpox Emergency Stockpile